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IntroductIon
Antiphospholipid syndrome (APS) is characterized by
arterial, venous and small vessel thrombosis and/or
pregnancy morbidity occurring in patients with per-
sistently positive antiphospholipid antibodies (aPL).
Catastrophic antiphospholipid syndrome (CAPS) is
the most severe, life-threatening variant of APS1. It is
characterized by small vessel thrombosis developing
over a short period of time in multiple organs, resul ting
in multiorgan dysfunction and often failure, with very
high mortality rates. In 2002 the proposed preliminary
classification criteria for CAPS were accepted (Table I)2.
Etiology and the pathogenesis of CAPS are unknown
at present. It has been hypothesized that a specific
trigger or multiple triggers, like infection, anticoagula-
tion withdrawal followed by surgery or biopsy, tissue
necrosis or thrombosis in patients with positive aPL can
lead to cytokine overproduction with development of
systemic inflammatory response syndrome and diffuse
small vessel thrombosis resulting in CAPS3.
Early and correct diagnosis and improvement in
therapy has led to decrease in mortality rates from 53%
in patients diagnosed before 2001 to 33% in those di-
agnosed between 2001 and 20054. Improvement in
therapy is the consequence of using combined therapy
comprised of anticoagulation, glucocorticoids, plasma
exchange and/or intravenous immunoglobulins with
identification and treatment of any precipitating factor
as a first line of therapy5. The use of cyclophosphamide
is associated with increased survival rates in patients
with systemic lupus erythematosus associated CAPS
(SLE-CAPS) and has a worsening effect on the survival
of patients with primary CAPS (P-CAPS). Generally pa-
tients with SLE-CAPS have a higher mortality risk than
patients with P-CAPS6. Despite the use of first line ther-
apy there is still a significant proportion of patients who
will suffer from recurrent episodes of CAPS or who will
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AbstrAct
Catastrophic antiphospholipid syndrome (CAPS) is a
rare, acute, life-threatening form of antiphospholipid
syndrome. In the last several decades there has been a
significant improvement in the treatment of patients
with CAPS, but the overall mortality is still very signi -
ficant. The use of rituximab has been reported in the
treatment of refractory cases of CAPS but the data are
still scarce and inconclusive. We report a case of 47-
-year-old male patient with long standing SLE and
secon dary APS who presented with acute thromboem-
bolic incident (partial thrombosis of superior mesen-
teric artery). During the first week of his hospitalization
he met the criteria for probable CAPS. He was treated
with anticoagulants, glucocorticoids, intravenous im-
munoglobulins and systemic antibiotics. Finally he was
treated with rituximab. There was no response to the
implemented treatment and he eventually died. Au-
topsy showed evidence of small vessel thrombosis in
the lung microvasculature. With this the criteria for
definitive CAPS were fulfilled. To our knowledge, at
present time, this is the first ever reported case of defini-
tive CAPS associated with SLE treated with rituximab.
There is a great need for further investigation to evalu-
ate the effectiveness of rituximab in treatment of CAPS.
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die from it being defined as having refractory CAPS7.
New biologic drugs such as rituximab, defibrotide and
eculizumab have been used in treatment of patients
with CAPS and refractory CAPS but there are no stu -
dies or guidelines for the usage of these agents.
Rituximab is a chimeric murine/human monoclo nal
antibody directed against the B-lymphocyte surface
antigen CD20. There are no available studies about the
use of rituximab in the treatment of CAPS. There are
only a few case reports and one systematic review so it
is still not possible to determine the influence of ritu -
ximab on the mortality rate of patients with CAPS.
Nevertheless there is a general agreement that it could
have a role in its treatment8. We present a case of CAPS
treated with rituximab in patient with SLE. To our
knowledge, our patient is the first ever to be reported
with definite CAPS associated with SLE and treated
with rituximab.
cAsE rEPort
We are presenting a 47-year-old male patient with a
13 year history of systemic lupus erythematosus and
secondary antiphospholipid syndrome. He initially
presented with deep venous thrombosis of right leg,
non-erosive arthritis, discoid rash, lymphopenia, posi -
tive titers of anti-nuclear antibodies (ANA) and anti-
-dsDNA, anticardiolipin IgG and IgM antibodies and
positive lupus anticoagulant (LAC). Despite combined
immunosupresive drugs (chloroquine, moderate to
high dose of prednisone and cyclophosphamide dur-
ing one period for suspected central nervus system lu-
pus) and adequate anticoagulant therapy he expe -
rienced seve ral arterial and venous thrombotic events
over the time. Given the refractory course of APS com-
bination of oral anticoagulant (warfarin) and an-
tiplatelet (acetylsalicylic acid) therapy was imple-
mented.
Three months before his last hospitalization, he de-
veloped acute pain and lividness of his second left toe.
Angiography was performed and occlusion of distal
part of left anterior tibial artery was found. Amputation
of ischemic toe was eventually performed. Taking into
account the extremely high titers of antiphospholipid
antibodies (positive LAC; anticardiolipin IgG anti-
bodies - highly positive; anticardiolipin antibodies IgM
- weakly positive; anti-beta2-glycoprotein-I IgG anti-
bodies - highly positive) and refractory course of the
disease with limited further therapeutic options, two
plasmapheresis were performed with the goal of low-
ering the titers of aPLs. Patient recovered well and was
tAbLE I. PrELImInAry cLAssIfIcAtIon crItErIA for cAtAstroPhIc AntIPhosPhoLIPId syndromE*
Preliminary classification criteria for catastrophic antiphospholipid syndrome
Criteria:
1. Evidence of involvement of three or more organs, systems and/or tissues.
2. Development of manifestations simultaneously or in less than a week.
3. Confirmation by histopathology of small vessel occlusion in at least one organ or tissue.
4. Laboratory confirmation of the presence of antiphospholipid antibodies (lupus anticoagulant and/or anticardiolipin
antibodies and/or anti-Beta2-glcyoprotein I antibodies)
Definite catastrophic APS
All four criteria
Probable catastrophic APS
All four criteria, except for only two organs, systems and/or tissues involvement
All four criteria, except for the absence of laboratory conformation at least six weeks apart due to the early death of a
patient never tested for aPL before the catastrophic APS
• 1, 2 and 4
• 1, 3 and 4 and the development of a third event in more than a week but less than a month, despite anticoagulation
APS, antiphospholipid syndrome; aPL, antiphospholipid antibodies
*adapted from Asherson2
fIGurE 1. Multi-slice computer tomography (MSCT) angiography of the abdomen and pelvis (with i.v. contrast agent):
A) Normal diameter and flow through superior mesenteric, splenic and portal veins. Normal size and structure of the kidneys,
spleen, pancreas and biliary tract. B) Partial thrombosis, with narrowing of the lumen (from approx. 6.6 to approx. 1.7 cm), of the
superior mesenteric artery approx. 2 cm from the starting point. 
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At that time the decision was made that the urgent
surgical or percutaneous endovascular intervention
would not be carried out. The option of thrombolysis
was also discussed but was rejected. He was treated
with wide spectrum antibiotics, pulses of methylpre -
dnisolone and periodic transfusions of packed red
blood cells. Warfarin was replaced with low molecular
weight heparin. During the next few days pain in the
abdomen persisted but there was no signs of acute peri-
tonitis or intestinal necrosis. There was a gradual de-
cline in acute phase reactants accompanied with an
signi ficant elevation in liver enzymes and creatinine
with mild proteinuria. There was a severe decline in
the platelets count (min. 6x109/L requiring transfusion)
and hemoglobin (min. 75 g/L when transfusion was
conducted) with prolongation of aPTT. LAC and IgG
anticardiolipine and anti-beta2-glycoprotein I anti-
bodies were again positive in high titer. Analysis of the
bone marrow was performed and showed a regular tri-
lineage hematopoesis. Autoimmune hemolytic anemia
and heparine induced thrombocytopenia were ex-
cluded. Initial blood smear showed no schistiocytes
but regarding the above, mentioned and elevated le -
vels of lactate dehydrogenase, microangiopathic ane-
mia was suspected. There were no clinical or laborato-
dismissed with the recommendation for oral methyl-
prednisolone (0.75 mg per kg/day with slow 
ta pering of the dose to 0.5 mg per kg/day), cyclo -
phosphamide (2 mg per kg/day), acetylsalicylic acid
(100 mg per day) and warfarin (targeted INR 2-3).
One month later he was admitted due to very strong
acute abdominal pain. On first examination in the
emergency department he was cardiorespiratory sta-
ble, afebrile and his abdomen was distended, painful
but there were no clinical signs of acute peritonitis.
Laboratory results showed anemia (Hb 70 g/L, normal
range 138-175 g/L), thrombocytopenia (T 78x109/L,
normal range 158-424x109/L), prolonged activated
partial thromboplastin time (aPTT 55.1 s, normal range
24-33 s), prothrombin time in therapeutic range (INR
2.2) with normal creatinine and urea with mildly ele-
vated aminotransferases (AST 49 U/L, normal range
11-38 U/L and ALT 82 U/L, normal range 12-48 U/L)
and g-GT (56 U/L, normal range <177 U/L) and nor-
mal alkaline phosphatase and total bilirubin with ele-
vated C-reactive protein (67,7 mg/L, normal range 0-5
mg/L). Additional tests were performed and mesente -
ric CT angio graphy showed a partial thrombosis of su-
perior mesenteric artery with 75% lumen occlusion
(Fi gure 1).
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ry sings of SLE activity. The diagnosis of CAPS was ma -
de (Table II) and intravenous immunoglobulines in do se
of 0.4 g/kg/day for five days were added to the therapy.
With combined therapy for CAPS the patient was
stable but the permanent deterioration in renal function
was recorded with permanent refractory thrombocy-
topenia. Three weeks after IVIGs were introduced to
the therapy two doses of rituximab (500 mg i.v.) were
administered within a 7-day interval. There was no
therapeutic response on administered therapy and fur-
ther deterioration of renal function with persisting
thrombocytopenia and anemia were recorded. Six day
after the administration of the second dose of ritu ximab
patient become acutely dyspneic developing partial res-
piratory insufficiency with the rise in serum acute phase
reactants so he had to be moved to the intensive care
unit. Computed tomography of the lungs was made
and bilateral ground-glass infiltrates with zones of
dense consolidation were verified. Bronchoscopy was
also made and Candida albicans and Streptococcus
species were isolated from lavage fluid. Cytome -
galovirus DNA (1.78x103 copies/ml) was detected in
plasma using quantitative polymerase chain reaction
(PCR) test. Therapy with piperacillin plus tazobactam,
teicoplanin and fluconazole was initiated. Because of
the possibility of CMV pneumonia therapy with gan-
tAbLE II. crItErIA for dIAGnosIs of dEfInItIvE cAPs In our PAtIEnt
Involvement of three or more organs, systems Laboratory Confirmation by 
and/or tissues (criteria 1) simultaneously or in less than confirmation of the histopathology of 
a week (criteria 2) presence of aPLs small vessel 
(LAC and/or aCLs)  occlusion in at  
– criteria 3 least one organ or 
tissue – criteria 4
Kidney Reference Admission Relevant Positive LAC, ab2- GPI small vessel
change in aCL-IgG (65 occlusion in lung
first week GPL-U/ml) and ab2- sample from autopsy 
creatinine (79-125 mmol/L) 96 160 GPI (112 RU/ml)
urea (2.8-8.3 mmol/L7,6) 13,2
proteinuria (negative++) (0,75 g/L)
Hepatic AST (11-38 U/L) 49 184
ALT (12-48 U/L) 82 243
g-GT (< 177 U/L) 56 84
T. bilirubine (3-20 mmol/L) 9 26
Partial 
thrombosis
Confirmed with MSCT angiography at admission
of superior 
(Figure 1)
mesenteric 
artery
Other 
findings 
prolonged activated partial thromboplastin time
suporting 
microangiopathic anemia and thrombocytopenia
the diagnosis
of CAPS
FULFILLMENT OF 1st AND 2nd CRITERIA FULFILLMENT OF FULFILLMENT OF 
3rd CRITERIA 4th CRITERIA
DIAGNOSIS OF PROBABLE CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME
DIAGNOSIS OF DEFINITIVE CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME
CAPS, catastrophic antiphospholipid syndrome; aPL, antiphospholipid antibodies; aCL, anticardiolipin antibodies; LAC, lupus
anticoagulant; ab2-GPI, antib2 glycoprotein 1; AST, aspartate aminotransferase; ALT, alanin aminotransferase; g-GT, gamma-glutamyl
transferase; MSCT, multislice computed tomography
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cyclovir was also applied. Partial clinical improvement
with gradual decline in acute phase reactants was
achieved but with persisting prolongation of aPTT, se-
vere thrombocytopenia and anemia demanding peri-
odic transfusions of blood products. Few days later sig-
nificant decline in renal function with hyperkalemia,
demanding the start of hemodyalisis, with severe pan-
cytopenia (L 0.5, Hb 76, T 10) and raise in acute phase
reactants were recorded. Transfusions of blood prod-
ucts were given together with granulocyte colony-stim-
ulating factor (G-CSF) filgrastim. Quantitative CMV
PCR plasma test was repeated and came back negative
so gancyclovir was excluded from thera py. Despite all
measures taken, the patient was permanently pancy-
topenic, in poor general condition. Soon he became
hemodynamically unstable and despite supportive
measures eventually died.
The autopsy was performed and evidence of small
vessel thrombosis was found in the lung microvascu-
lature (Figure 2). The criteria for the definite CAPS were
fulfilled.
dIscussIon
At the present time, there are no formal recommenda-
tions and guidelines and no studies on the use of ri -
tuximab in the treatment of CAPS. In the current lite -
rature 11 reports of 13 patients with CAPS treated with
rituximab can be found8-19. Berman et al. in their sys-
temic review included 9 more patients whose clinical
cases were never published8. Only 2 of the published
patients had CAPS associated with known or suspect-
ed systemic lupus erythematosus12,15. None of them met
the criteria for definite CAPS. Our patient is the first
ever to be reported with definite CAPS associated with
SLE and treated with rituximab. Reported patient did
not respond to the first line therapy for CAPS (gluco-
corticoides, anticoagulation and IVIGs). Treatment
with rituximab was also ineffective (Table III) and the
patient eventually died from refractory CAPS and com-
plications.
It is important to emphasize a number of factors
which probably contributed to the ineffectiveness of
the used therapeutic protocol. As already mentioned,
patients with CAPS associated with SLE have higher
mortality rates than patients with primary CAPS. Treat-
ment with cyclophosphamide has a favourable effect
in the treatment of this subgroup of patients. In the
des cribed patient, cyclophosphamide and plasma-
pheresis were not used in the first line of therapy. Con-
sidering triple positive aPLs in high titers, not using the
plasmapheresis could be an important contributing fac-
tor to the ineffectiveness of therapy. In addition it is im-
portant to say that the initially verified partial throm-
bosis of superior mesenteric artery was not resolved
during the course of disease. This could be a very im-
portant factor in the sustaining of pathogenetical
mecha nisms responsible for development of CAPS con-
sequently leading to ineffectiveness of used therapy.
Furthermore, time between the first line of the thera-
py and the introduction of rituximab was relatively
long. Prolonged course of the disease has lead to the de-
velopment of infectious complications that probably
also contributed to sustaining pathogenetical mecha-
nisms responsible for development of CAPS.
Whether more “aggressive” approach in dealing with
sustaining factors and simultaneous use of all current-
ly available therapeutic options as first line therapy
would have led to a greater effect or would have re-
sulted in earlier death is not possible to conclude at
this time.
concLusIon
We presented the first ever reported case of definitive
CAPS associated with SLE treated with rituximab. In re-
fIGurE 2. Hematoxylin and eosin stain, objective 10x, inlet
objective 40x. Presentation of infarcted (necrotic) area of the
lung where parenchymal architecture can hardly be recognized,
some alveolar spaces in the upper parts are filled with
abundant fibrin, interalveolar septa completely necrotic,
somewhere even completely missing. Small blood vessel with
the remnant of fibrinous thrombus in the middle of inlet
figure, favoring thrombosis as the most probable cause of
pulmonary hemorrhagic infarction in our patient. 
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ported patient combined therapeutic protocol (sys-
temic antibiotics, glucocorticoids, anticoagulation,
IVIGs) with rituximab was ineffective. We listed a num-
ber of factors that could have influenced the final result.
The right timing for the introduction of rituximab is
still uncertain. Whether the course of the disease would
have been changed if the rituximab was started earlier
is also unknown. There is a great need for further in-
vestigation to evaluate the effectiveness of rituximab in
treatment of CAPS and to define the optimal regime
and timing of implementation. It is also necessary to de-
termine possible differences in effectiveness on patients
with primary CAPS and CAPS associated with SLE and
to determine possible other prognostic factors that
could influence therapeutic decisions and results.
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